Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Mar 08, 2022 8:00 AM - Mar 09, 2022 5:00 PM

(US Eastern Standard Time)

Advertising and Promotion Regulatory Affairs Conference

ADPROMO 2022 HAS GONE VIRTUAL! #AdPromo22 is now a fully virtual event. Use code ADPROMO2022 by March 7 to save $150 for this discounted rate, and join us from the comfort of your home or office. Register today!

Session 2: From Unbranded to Branded: The Role and Risks of Disease Awareness

Session Chair(s)

Virginia  Foley

Virginia Foley

VP Regulatory Lead, Life Sciences & Healthcare

Constellation, United States

Historically regarded as non-promotional communications, disease awareness and help-seeking communications have surged and evolved over time. This session will explore what it means to actively promote and advertise a disease or condition – as opposed to a product – in the current legal and regulatory landscape. Approaches and best practices pre- and post- product approval may vary, including when disease awareness is conducted, the scope and extent of disease state or treatment information (e.g., product classes, treatment options), who shares it (e.g., Marketing, Medical, or Sales functions), to whom it is shared (consumers vs. healthcare providers), and why. Panelists will discuss whether the traditional considerations and hallmarks of disease awareness communications still apply in light of newer digital technologies and FDA’s First Amendment policy. Finally, this session will highlight related advertising activities – neither branded nor disease state education – in the form of unbranded ads such as digital banners and sponsored links.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Recognize material differences for disease awareness in unbranded and branded communications
  • Identify best practices for disease awareness communications pre- and post-approval
  • Evaluate promotional risks and mitigation strategies
  • Understand that current legal and regulatory policies create uncertainty and require thoughtful evaluation for disease awareness activities

Speaker(s)

Virginia  Foley

Speaker

Virginia Foley

Constellation, United States

VP Regulatory Lead, Life Sciences & Healthcare

Michael A. Sauers, RAC

Speaker

Michael A. Sauers, RAC

Eli Lilly and Company , United States

Director, Global Regulatory Affairs - Advertising and Promotion

Dara S. Katcher Levy, JD

Speaker

Dara S. Katcher Levy, JD

Hyman Phelps & McNamara P.C., United States

Director

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.